US Broker Ratings

Integer Holdings Corporation (ITGR) Stock Analysis: Potential Upside and Strong Buy Ratings in the Medical Device Sector

Investors eyeing the healthcare sector might find Integer Holdings Corporation (NYSE: ITGR) an intriguing opportunity with its robust position in the medical device industry. With a market capitalization of $3.03..

Danaher Corporation (DHR) Stock Analysis: Exploring a 34% Potential Upside Amid Strong Buy Ratings

Danaher Corporation (NYSE: DHR), a stalwart in the healthcare sector, continues to capture the attention of investors with its solid performance and promising growth potential. Operating through its biotechnology, life..

Smith & Nephew SNATS, Inc. (SNN) Stock Analysis: Healthcare Giant with a 17.86% Upside Potential

Smith & Nephew SNATS, Inc. (NYSE: SNN) stands as a prominent player in the healthcare sector, specializing in medical devices. With a market capitalization of $12.62 billion, this UK-based company..

Royalty Pharma plc (RPRX) Stock Analysis: Evaluating Its 6.26% Potential Upside and Strong Buy Ratings

Royalty Pharma plc (NASDAQ: RPRX) stands out in the biotechnology sector, not just for its unique business model as a buyer of biopharmaceutical royalties but also for its robust market..

Cardinal Health, Inc. (CAH) Stock Analysis: Capitalizing on a 24.63% Potential Upside

Cardinal Health, Inc. (CAH) stands as a formidable player in the healthcare sector, specifically within the medical distribution industry. Headquartered in Dublin, Ohio, this Fortune 500 company operates globally, offering..

Alkermes plc (ALKS) Stock Analysis: Solid Growth Potential with 28.2% Revenue Surge and Analyst Consensus

Alkermes plc (NASDAQ: ALKS), a prominent player in the healthcare sector, operates within the specialty and generic drug manufacturing industry. Headquartered in Dublin, Ireland, Alkermes has carved a niche for..

Koninklijke Philips N.V. (PHG) Stock Analysis: Exploring a 27% Potential Upside for Investors

As Koninklijke Philips N.V. (NYSE: PHG), a stalwart in the healthcare sector, continues to navigate the challenging landscape of the medical devices industry, investors are keenly eyeing its growth potential..

Option Care Health, Inc. (OPCH) Stock Analysis: Unveiling a 39.83% Upside Potential

Option Care Health, Inc. (NASDAQ: OPCH) stands as a significant player in the healthcare sector, specializing in home and alternate site infusion services across the United States. With a market..

Jazz Pharmaceuticals (JAZZ) Stock Analysis: A Biotech Powerhouse with Strong Buy Ratings and Growth Potential

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) stands as a formidable entity within the biotechnology industry, hailing from Ireland and making significant strides in healthcare innovation. With a robust market capitalization of..

Bristol-Myers Squibb (BMY) Stock Analysis: Navigating a 10.32% Potential Upside Amidst Healthcare Innovation

Bristol-Myers Squibb Company (NYSE: BMY), a titan in the global biopharmaceutical industry, is capturing investor attention with a potential 10.32% upside based on its current average target price. As a..

Novartis AG (NVS) Stock Analysis: Evaluating the 2.46% Upside Potential in a Dynamic Healthcare Market

Novartis AG (NYSE: NVS), a leading player in the global pharmaceutical industry, continues to capture investor interest with its robust portfolio and strategic growth initiatives. Headquartered in Basel, Switzerland, Novartis..

Teleflex Incorporated (TFX) Stock Analysis: A Healthcare Player with 11.68% Upside Potential

Teleflex Incorporated (NYSE: TFX), a prominent player in the healthcare sector, has established itself as a leading manufacturer and supplier of single-use medical devices. With a market capitalization of $5.69..

Charles River Laboratories (CRL): Investor Outlook Reveals 17.46% Potential Upside

Charles River Laboratories International, Inc. (NYSE: CRL) stands as a prominent player in the healthcare sector, specifically within the diagnostics and research industry. With a market capitalization of $8.7 billion,..

Madrigal Pharmaceuticals, Inc. (MDGL): Investor Outlook Reveals 35.71% Potential Upside

Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL), a prominent player in the biotechnology sector, is capturing investor attention with its innovative focus on treating metabolic dysfunction-associated steatohepatitis (MASH). The company’s flagship product,..

BridgeBio Pharma, Inc. (BBIO) Stock Analysis: Exploring a Promising 54.93% Upside Potential

BridgeBio Pharma, Inc. (NASDAQ: BBIO) is capturing investor attention with its remarkable potential upside of 54.93%, according to recent analyst ratings. As a biotechnology company focused on developing treatments for..

Centene Corporation (CNC) Stock Analysis: Navigating Uncertainty with Strategic Healthcare Plans

Centene Corporation (NYSE: CNC), a formidable player in the healthcare sector, is currently grabbing investor attention with its strategic positioning within the healthcare plans industry. With a market capitalization of..

Regeneron Pharmaceuticals, Inc. (REGN)

⚠️ No article content returned.

..

Hologic, Inc. (HOLX) Stock Analysis: Navigating Modest Growth and Strategic Stability

Hologic, Inc. (NASDAQ: HOLX), a prominent player in the healthcare sector, is known for its innovative medical instruments and supplies, particularly in women’s health. Headquartered in Marlborough, Massachusetts, this $16.97..

Telix Pharmaceuticals Limited (TLX): Analyst Consensus Reveals 124.98% Potential Upside

Telix Pharmaceuticals Limited (ASX: TLX), an innovative player in the biotechnology sector, is garnering attention from investors due to its promising growth trajectory. With its headquarters in North Melbourne, Australia,..

Ascendis Pharma A/S (ASND) Stock Analysis: A 33% Upside Potential in the Biotech Sector

Ascendis Pharma A/S (NASDAQ: ASND) is gaining considerable attention in the biotechnology sector, primarily due to its promising pipeline and robust financial metrics. As a Denmark-based biopharmaceutical company, Ascendis focuses..

Search

Funds

US Broker Ratings

Search

Funds

US Broker Ratings

FTSE 100

Funds